Pharmacology of INS37217 [P1(uridine 5′)-P4 -(2′-deoxycytidine 5′)tetraphosphate, tetrasodium salt], a next-generation P2Y2receptor agonist for the treatment of cystic fibrosis

B. R. Yerxa, J. R. Sabater, C. W. Davis, M. J. Stutts, M. Lang-Furr, M. Picher, A. C. Jones, M. Cowlen, R. Dougherty, J. Boyer, W. M. Abraham, R. C. Boucher

Research output: Contribution to journalArticlepeer-review

136 Scopus citations


INS37217 P1 5′)-P4-(2′-deoxycytidine 5′)tetraphophate, tetrasodium salt] is a deoxycytidine-uridine dinucleotide with agonist activity at the P2Y2 receptor. In primate lung tissues, the P2Y2 receptor mRNA was located by in situ hybridization predominantly in epithelial cells and not in smooth mus- cle or stromal tissue. The pharmacologic profile of INS37217 parallels that of UTP, leading to increased chloride and watersecretion, increased cilia beat frequency, and increased mucin release. The combined effect of these actions was confirmed in an animal model of tracheal mucus velocity that showed that a single administration of INS37217 significantly enhanced mucus transport for at least 8 h after dosing. This extended duration of action is consistent with the ability of INS37217 to resist metabolism by airway cells and sputum enzymes. The enhanced metabolic stability and resultant increased duration of improved mucociliary clearance may confer significant advantages to INS37217 over other P2Y2 agonists in the treatment of diseases such as cystic fibrosis.

Original languageEnglish (US)
Pages (from-to)871-880
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Issue number3
StatePublished - Sep 2002

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Pharmacology of INS37217 [P<sup>1</sup>(uridine 5′)-P<sup>4</sup> -(2′-deoxycytidine 5′)tetraphosphate, tetrasodium salt], a next-generation P2Y<sub>2</sub>receptor agonist for the treatment of cystic fibrosis'. Together they form a unique fingerprint.

Cite this